New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses

Migraine is an idiopathic, recurrent neurovascular headache disorder characterised by attacks of debilitating pain associated with photophobia, phonophobia, nausea and vomiting. It is apparently a global disorder, occurring in all races, cultures and geographical locations. Migraine has a hereditary component, and its life-time prevalence is about 16%. About a third of migraine patients in Sweden seem to be particularly sorely afflicted having 1-6 severe attacks a month and accounting for more than 80 per cent of the annual total of about 14 million attacks in the country as a whole. In general, these migraine sufferers do not obtain satisfactory relief from simple analgesice or NSAIDs (non-sterodial antiinflammatory drugs only), and thus require additional migraine-specific treatment. Selective 5-HT1B/1D-agonists, the so-called triptans, have become an invaluable addition to the therapeutic arsenal for treating this category of patients.

Medienart:

Artikel

Erscheinungsjahr:

1998

Erschienen:

1998

Enthalten in:

Zur Gesamtaufnahme - volume:95

Enthalten in:

Lakartidningen - 95(1998), 46 vom: 11. Nov., Seite 5175, 5178-82, 5184-6

Sprache:

Schwedisch

Weiterer Titel:

Nya triptanpreparat kan hjälpa migränpatienten. Farmakodynamiska och farmakokinetiska framsteg

Beteiligte Personen:

Dahlöf, C G [VerfasserIn]

Themen:

8R78F6L9VO
Analgesics
English Abstract
Journal Article
Review
Serotonin Receptor Agonists
Sumatriptan
Vasoconstrictor Agents

Anmerkungen:

Date Completed 07.01.1999

Date Revised 21.11.2013

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM097790109